Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $21.8 million.

  • NewAmsterdam Pharma's Gains from Investment Securities rose 788.76% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 788.76%. This contributed to the annual value of $19.0 million for FY2024, which is 2056.29% up from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Gains from Investment Securities of $21.8 million as of Q3 2025, which was up 788.76% from $22.2 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Gains from Investment Securities' 5-year high stood at $22.2 million during Q2 2025, with a 5-year trough of $1.6 million in Q3 2023.
  • Moreover, its 4-year median value for Gains from Investment Securities was $19.8 million (2024), whereas its average is $16.1 million.
  • In the last 5 years, NewAmsterdam Pharma's Gains from Investment Securities surged by 116130.96% in 2024 and then skyrocketed by 788.76% in 2025.
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Gains from Investment Securities stood at $11.4 million in 2022, then tumbled by 85.93% to $1.6 million in 2023, then soared by 1056.25% to $18.5 million in 2024, then grew by 17.69% to $21.8 million in 2025.
  • Its Gains from Investment Securities stands at $21.8 million for Q3 2025, versus $22.2 million for Q2 2025 and $21.9 million for Q1 2025.